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Abstract
Objectives—To compare the health-related quality of life (HRQoL) of children with CKD and
short stature (SS) to children with CKD and normal height (NH), to evaluate the impact of catch
up growth and growth hormone use on HRQoL, and to describe the concordance of perceptions of
HRQoL between children with SS and NH and their parents.
Study design—483 children and/or parents enrolled in the multicenter CKiD study and had
completed the Pediatric Quality of Life Inventory (PedsQL, V4.0) on at least two CKiD study
visits comprised this sub-study population. Participants were dichotomized into NH or SS groups.
The demographic characteristics that varied at baseline (sex, GFR and parent education) were
© 2013 Mosby, Inc. All rights reserved.
*Corresponding author: Amira Al-Uzri, M.D., MCR., Associate Professor, Pediatrics, Oregon Health & Science University,
Department of Pediatrics, Division of Pediatric Kidney Services and Hypertension, 707 SW Gaines Road-CDRCP, Portland, OR
97239, Phone: 503-494-7327, Fax: 503-418-6718, aluzria@ohsu.edu.
*A list of members of the Chronic Kidney Disease in Children (CKiD) Study Group is available at www.jpeds.com (Appendix).
The authors declare no conflicts of interest.
Portions of the study were presented as a poster at the American Society of Nephrology’s meeting, November 19, 2010, Denver, CO.
Registered with ClinicalTrials.gov:
No reprints are requested
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Pediatr. Author manuscript; available in PMC 2014 September 01.
Published in final edited form as:













controlled for in the main analysis evaluating the impact of catch up growth and use of growth
hormone on HRQoL.
Results—Multivariate modeling (controlling for confounding variables) revealed a significant
association between both catch up growth and growth hormone usage on parent-proxy reports of
child physical functioning (p<.05) and social functioning (p<.05). Older children with CKD (15 to
17 years old) had significantly higher ratings than their parents on PedsQL Physical, Emotional,
Social and School Functioning scales compared with younger children (8–14 years old).
Conclusion—The finding that height gains and growth hormone use are associated with
increases in physical and social functioning by parent report provides additional support for
interventions to improve height in children with CKD. The importance of evaluating both the
parent and child perceptions of HRQoL is supported by our results.
Short stature (SS) is common in children with chronic kidney disease (CKD) due to multiple
factors (1). A study published by the North American Pediatric Renal Trials and
Collaborative Studies (NAPRTCS) reported that 36 % of children with CKD had height Z
score < −1.88 at time of enrollment (5).
Research evidence in non-CKD populations demonstrates that taller stature is equated with
better health, better income (6, 7), more social opportunities, and fewer behavioral problems
(8, 9). In addition, published research in non-CKD populations has reported that compared
with children with NH, children with SS have poorer school performance (10, 11), lower
self-esteem, difficulties with adaptation, teasing in school and juvenilization (12, 13). It is
also important to point out that some research with children has not observed a relationship
between height and various aspects of HRQoL.
Recent evidence points to the impact of chronic kidney disease on HRQoL. For example,
cross-sectional data demonstrated that children with CKD to have lower HRQoL scores
compared with healthy children (14). Of particular relevance to the present study was the
findings that children with SS (less than the 5th percentile corrected for age) had twice the
odds of having impaired HRQoL compared with children with CKD and normal height (14).
One of the common methodological criticisms of previously published pediatric HRQoL
research is the use of a single informant (i.e. either parent or child). Observations of parent-
child disagreement about HRQoL, particularly prominent in adolescent populations, have
led to endorsement of multi-informant ratings of HRQoL (15, 16).
This report expands on previously published research evaluating the association between
height and HRQoL in children with CKD using a longitudinal data set. The aims of this
study were threefold: (1) to compare the HRQoL of children with mild to moderate CKD
and SS with that of children with CKD and NH; (2) to evaluate the impact of increases in
height and growth hormone use on HRQoL; and (3) to investigate the concordance of parent
and child perceptions of HRQoL in children with SS and NH.
Methods
This study uses data collected in the multicenter CKiD study. The CKiD study design and
objectives have been previously described (17). In brief, CKiD is a prospective,
longitudinal, observational study of children with CKD who are enrolled at ages 1–16 years.
The study protocol includes periodic assessments of HRQoL of children ages 8 years and
older and their parents. This study is comprised of 483 children who were recruited into
CKiD and who had at least two evaluations of their HRQoL. Height and HRQoL data were
collected at approximately six months, one year, and two years after study entry. The CKiD
study was approved by the Institutional Review Board of each participating clinical site.
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All children had mild to moderate CKD with an estimated glomerular filtration rate ranging
between 30–90 ml/min/1.73m2 calculated by the Schwartz formula at study enrollment (18).
Height was measured at all study visits using a stadiometer in all children > 2 years who can
stand and length was measured in children who are unable to stand by using a firm box in
the supine position (17). The subjects in this study were dichotomously divided into the
short stature or normal height group. Short stature is defined as having a height less than or
equal to the 3rd percentile for age and sex, corresponding to a height Z score of −1.88 or
lower at the time of study enrollment. Children who did not fit the definition of SS were
considered to have normal height for their age and sex. The SS definition used in this report
matches the criteria used by the FDA in approving growth hormone therapy in children with
CKD as well as in efficacy trials of growth hormone for children with CKD and SS (19).
Kidney function was measured at the initial study visit using the plasma disappearance of
iohexol (iGFR) (18).
The 23-item Pediatric Quality of Life Inventory (PedsQL™, Version 4.0) (20) was used to
evaluate HRQoL. The PedsQL assesses the problem frequency within the domains of
physical, emotional, social, and school functioning. Responses for items on the PedQL are
summed and transformed into a score ranging from 0–100. Higher scores suggest a better
HRQoL. All parents filled out the parent-proxy version of PedsQL. Parents of children older
than 8 years and their child completed age-specific forms. Some of the analyses reported
below used parent/child dyad data, and other analyses were not restricted in this manner.
Statistical Analyses
The main outcome in this study was HRQoL measured using the PedsQL Overall score and
scores for each of the four PedsQL subscales (Physical Functioning, Social Functioning,
Emotional Functioning, and School Functioning). Baseline HRQoL was measured at the
second (6 months) CKiD study visit. Confounding variables were identified using two-
sample t-tests. Next, univariate relationships between groups (SS and NH) and HRQoL, but
not controlling for confounding variables, were computed. Additionally, within each stature
group, we used t-tests to compare HRQoL between children on GH therapy and children not
on GH (p-values less than 0.05 were considered to be statistically significant).
For the second research question we conducted longitudinal analyses incorporating height
data from visits at six months (baseline), one year, and two years after study entry. A simple
mixed model linear regression was used to assess whether height Z-score increased over
time, particularly in those with SS at baseline. For this analysis the only predictor variable
was short stature at baseline and the outcome variable was height Z-score.
To determine the strength of the longitudinal relationship between height and HRQoL, a
multivariate mixed model regression approach was used to examine the relationship between
height Z-score and HRQoL among only the children with SS at baseline, accounting for
repeated measures and adjusting for growth hormone use at baseline, age, sex, maternal
education and ieGFR. Due to the fact that iohexol-based GFR is not measured at all visits,
estimated GFR (eGFR) is calculated when iGFR is not available to complete the
longitudinal data; ieGFR is defined as iGFR if it is available, eGFR if it is not. This analysis
allowed us to assess whether catch-up growth in children with SS affected their HRQoL
while controlling for potential confounders.
To assess for an effect of GH therapy on HRQoL, GH was considered a separate predictor
variable, not merely a surrogate marker for height within the mixed model regression
analysis.
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Our final analysis evaluated agreement in ratings in all domains between parent and child
HRQoL. A longitudinal mixed model regression method specifically designed to evaluate
concordance between two raters was used. The model estimates correlation; bias, defined as
average difference between child and parent rating; and the difference in dispersion of
scores within groups (defined as the ratio of the standard deviations). Necessarily, we
restricted this analysis to parent-child dyads with HRQoL scores. We examined agreement
separately for children less than 15 years old versus 15 or older. We considered fifteen years
as representing mid-adolescence that defines the start of the transitioning phase into
adulthood (21, 22) during high school years.
These analyses were conducted using SAS version 9.2.
Results
The age range of children in this study at baseline was 2 to 17 years and was 3–18 years at
the time of analysis. Of the 483 subjects, 297 (61.5%) were males and 71 (15%) had SS at
baseline. Among children with SS, only 17 (24%) were on GH. Among children with NH,
41 (10%) were on GH therapy.
The two groups were comparable at baseline in all characteristics except sex, iGFR, and
maternal education. Compared with the SS group, a higher percentage of males, a higher
iGFR, and higher maternal education were observed in the NH group (Table I).
Comparison of Patients with CKD with and without Short Stature
The mean scores for each domain for PedsQL completed by parents and children are
displayed in Table II. Univariate group comparisons suggested that parent-reported physical
HRQoL was lower in the SS group compared with the NH group but the difference did not
reach statistical significance (p=.054). The effect size for this group difference is in the
small to moderate range (Cohen d =.315).
Longitudinal Analysis of Growth and HRQoL
Longitudinal analysis of growth was performed after excluding six subjects whose growth
patterns suggested measurement errors (ie, substantial decline in height, growing then
shrinking, or shrinking then growing). The results of this analysis indicated that children
with SS at baseline had a positive change in their height Z score over time (p <0.0001)
indicating significant growth, and those with NH did not show significant change in their
height Z- score (p >.05).
When assessing whether catch-up growth in children with SS was associated with
improvements in HRQoL, increase in height Z-score (controlling for use of growth
hormone, sex, child age, ieGFR and maternal education) was significantly associated with
an approximate 7 point increase in PedsQL parent-proxy perception of physical functioning
and social functioning of children. Conversely, no significant association between catch up
growth and improvement in HRQoL was seen with analyses of child-completed PedsQL
data (Table III). Other findings of this analysis include the observation that child age was
inversely associated with parent observations of their child’s physical, emotional, social,
school and overall HRQoL (Table III). In order to evaluate potential age-related bias we
conducted an analysis of PedsQL data from Parent/Child dyads. We observed that the trends
in parent reported HRQoL domain scores remained significant for physical domain
(p=0.03), yet others did not reach statistical significance when compared with all-age parent
HRQoL scores (data not presented).
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When the two groups were further subdivided into those taking versus not taking growth
hormone, there were a total of 58 children on GH therapy in the study population (12% of
study sample). Univariate relationships were not observed in any of the PedsQL subscales
among those who were on GH therapy compared with those who were not on GH within
each stature group (data not shown). Alternatively, multivariate modeling confirmed a
significant impact of improved height Z- score with growth hormone usage on parent-
reported physical functioning (p<.05) as well as social functioning (p<.05) of their children
(Table III).
Parent and Child Agreement on HRQoL Ratings
The analysis of agreement between parent and child ratings on the PedsQL subscales was
performed for parent-child dyads of younger (8–14 years) versus older children (15–17
years) (Table IV). This analysis showed a statistically and clinically important discordance
between the parent and child PedsQL scores in the older adolescents, with this group of
patients reporting significantly higher scores than their parents in all PedsQL domains
except school performance. In addition, the analysis showed a wider dispersion in the parent
PedsQL scores compared with teen scores in the adolescent group. In comparison, a high
level of concordance between parent and child PedsQL scores was observed in the younger
group, except in the emotional functioning subscale. On average, younger children rated
their emotional functioning worse than did their parents. Similar to the older adolescent
group, there was a larger dispersion in the parent versus child scores.
Discussion
The use of GH is not a universally accepted clinical practice in children with CKD(23)
despite the positive effect of GH therapy on height (24). It has been speculated that the
absence of research demonstrating a definitive difference in the HRQoL of children with SS
and NH, as well as the absence of research demonstrating that improvements in height are
associated with improvements in HRQoL has hindered the widespread use of GH treatment
of children with SS (5, 12, 23). The present study sought to provide some empirical support
for the relationship between improved height and improved HRQoL in youth who have mild
to moderate CKD. One of the study’s strengths is the use of a longitudinal data set with a
large cohort of children. These study design factors allowed for an unprecedented
characterization of the relationship between growth and HRQoL in children with CKD over
a period of several years.
We know from a previous publication based on data from the CKiD study that children with
CKD have lower HRQoL scores compared with healthy children and that children with SS
and CKD had double the odds of a more impaired HRQoL (14). The association between
height and HRQoL was replicated and extended in the present study using a more stringent
criterion to define SS (less than the 3rd percentile corrected for age and sex) and a
longitudinal data set.
With regard to the demographics of our study population, we found a lower percentage of
males among the SS group compared with the NH group. This finding may reflect sex bias
in favor of boys that had been reported previously in children referred for treatment with
growth hormone (25, 26). We also found a lower iGFR in children with SS compared with
NH with a mean difference of 7.8 ml/min|1.73m2. This finding is similar to previous reports
that show poorer growth in association with lower GFR (27). In addition, maternal education
differences were observed, with mothers of children in the NH group displaying higher
educational achievement than mothers of children in SS group. This new finding in children
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with CKD and SS is in contrast to a published report about the lack of difference in maternal
education between children with SS versus NH in the general population (28). Differences
in population characteristics and cause of SS may account for the different results observed
in our study. Even after controlling for the aforementioned confounding variables, support
for the association between height gains and HRQoL improvement was observed.
Our data show significant associations between improvement in height Z-scores and better
HRQoL scores in the physical functioning and social functioning domains by parent proxy.
Our interpretation of this finding is that parents of children with SS consider the physical
and social functioning to be similarly impacted by growth.
This finding also provides support for including HRQoL in clinical decision making
regarding the initiation of growth hormone therapy in children with CKD and SS. In
comparison with parent attributions of height gains and improved HRQoL, children with
height gains (improved Z-scores) did not report concomitant improvements in ratings of
their HRQoL. These discrepant results can be interpreted in a variety of ways. Some are
inclined to conclude that HRQoL is more important/valid if assessed by parents rather than
children. Others may interpret this finding to support adherence with the recent
recommendations to query both parents and children when evaluating the quality of life of
children with chronic medical problems so as to obtain the most comprehensive assessment
(15, 16). Alternatively, this finding may be dismissed as a statistical artifact that results from
higher child reported PedsQL scores at baseline.
Consistent with previously published studies, concordance of youth and parent perceptions
of HRQoL were age dependent (15). Our study observed a lower correlation between self
and parent proxy PedsQL scores related to physical functioning, emotional functioning and
social functioning among adolescents compared with younger patients with CKD. Parent
ratings of their adolescent’s physical, emotional, and social functioning were lower than
adolescent ratings of the same aspects of HRQoL. These findings may signify increased
parent concern regarding the long-term impact of CKD on HRQoL. Conversely, adolescents
may not share their parents’ worry (15, 16). These findings provide additional support for
the importance of ongoing assessment of HRQoL in children with both SS and NH from
both parental and youth perspectives.
The finding that a large number of children with SS are not receiving GH therapy (76%)
concurs with previous reports about the low utilization of GH in children with CKD (5).
Early referral for kidney transplantation, financial burden of GH therapy, the requirement
for daily injection, and the parent’s concern of long-term side effects may all play a role in
parental decisions regarding GH use.
It is important to point out several study characteristics that may limit the generalizability of
the findings. First, the relatively small number of children on GH therapy may have limited
our ability to detect any differences in the HRQoL scores between those with SS and those
with NH. Second, a two year follow-up may not be sufficient to reliably determine the type
and magnitude of the relationship between height improvements and HRQoL. Lastly, the
use of a generic HRQoL instrument may not be as sensitive in detecting changes in HRQoL
as a disease-specific HRQoL instrument (29).
In summary, the finding that height gains in children with SS and CKD are associated with
parent perception of youth HRQoL in the domains of physical and social functioning
provide additional support for interventions that are likely to optimize final height in this
population, including earlier use of GH therapy. Sharing these study findings with parents of
children with CKD and SS may improve parent acceptance of physicians’ recommendations
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for GH therapy. Sharing these study findings with health care providers may change care
practice.
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Table 1
Demographics of participants at baseline.
Characteristic Short Stature (SS) (N=71) Normal Height (NH) (N=412)
Age (y) mean ± SD 10.37 ± 4.47 11.28 ± 4.31
Age < 8 years 23 (32%) 98 (24%)
Male* 36 (51%) 261 (63%)
African-American race 12 (17%) 84 (20%)
Hispanic ethnicity 12 (17%) 61 (15%)
Maternal Education*
 High School or Less 38 (56%) 163 (40%)
 Some College 16 (24%) 114 (28%)
 College or More 14 (21%) 128 (32%)
iGFR (ml/min|1.73m2)* mean ± SD 40.03 ± 17.48 47.83 ± 18.19
Glomerular CKD etiology 16 (23%) 94 (23%)
*
p < 0.05 for difference between groups.
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